Overview

Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2028-08-31
Target enrollment:
Participant gender:
Summary
To confirm the tolerability and safety of combined administration of ONO-4059 and R-MPV therapy in untreated PCNSL patients.
Phase:
PHASE1
Details
Lead Sponsor:
Ono Pharmaceutical Co. Ltd
Treatments:
Methotrexate
Procarbazine
Rituximab
tirabrutinib
Vincristine